Technological advances are moving drug discovery work to computers, but experimental medicines still must be tested in animals. Startup Manifold Bio is developing technology that enables the testing of hundreds of molecules in a single mouse, bringing drug hunters valuable in vivo data much earlier in the drug discovery process.
Nabla Bio emerged from the lab of famed Harvard scientist George Church last year, and its antibody discovery technology has already led to five partnerships with pharma and biotech companies. The startup just closed an $11 million seed financing that will support further development of its technology.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
PlateletBio trails Sanofi among others in pursuit of a new therapy for a rare blood clotting disorder that has few treatments. But the biotech startup could stand apart from those drugs with its new class of cell therapy, which harnesses the properties of platelets.
Harvard University spinout GRO Biosciences has technology offering the potential for protein therapies that are safer and more effective than currently available biologic drugs. The startup's research is now backed by $25 million, a Series A financing round whose investors include the venture arm of Bayer.
Biomanufacturing technologies company Resilience is partnering with Harvard in a deal that could see innovations from the university’s labs commercialized under new businesses. Resilience has committed $30 million in funding to support Harvard biomanufacturing research.
The study, by researchers at Harvard, MIT, The Broad and other institutions, used genomic analysis of cases linked to the Biogen meeting, linking much of the community transmission in the Boston area to a European genetic variant of SARS-CoV-2 that first appeared at the meeting.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
In an opinion article in the New England Journal of Medicine, Drs. Benjamin Rome and Jerry Avorn of Harvard University wrote that advocating quick FDA approval for hydroxychloroquine and chloroquine despite paucity of evidence "runs counter to the idea of evidence-based medicine."
The decision in favor of Broad Institute of MIT and Harvard by a panel of judges at the US Court of Appeals for the Federal Circuit leaves UC Berkeley with few options to appeal further.
The device could be the next evolution in assistive technology, helping manage congestive heart failure more safely.
Thursday, the NFLPA and Harvard's Football Players Health Study released TeamStudy, an iPhone app built on ResearchKit framework.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The Harvard University spinout's aim is to cost-effectively match patients with drugs that will actually work - that is, seek out a cocktail of HIV medication to which they aren't resistant.
Neurotrack has announced the availabilty of its webcam-based test that is aimed to help those with diseases like Alzheimer's track recognition memory and cognitive function in order to detect risks before behavioral symptoms show up - and it only takes five minutes.
The biotech IPO parade marches on with two IPOs: Wave Life Sciences priced out at $102 million today, and Voyager Life Sciences raised $70 million.
Creating medical supplies as needed using 3D printing could be a more efficient way to cut costs and customize care.
Cambridge startup Ultivue just closed out a $5.15 million Series A for its reagent kits that help researchers inexpensively achieve extremely high resolution microscopy. Notably, Illlumina cofounder David R. Walt helped launch the company.